ACC 2023 Esperion's Outcomes win looks lackluster

Quote

anonymous

Guest
This is the title of Madeline Armstrongs article in Evaluate.com. " a 13% reduction in risk of cardiovascular events is statistically significant but not spectacular ". This is the reality of the data. The coveted 20% reduction for most cardio trials wasn't met. The article really points out the uphill road Esperion has in convincing cardiologist to prescribe. It was a good effort that fell short. Still admirably that a study was able to enroll close to 14,000 patients through a pandemic but very unfortunate that data wasn't robust.
 






anonymous said:
This is the title of Madeline Armstrongs article in Evaluate.com. " a 13% reduction in risk of cardiovascular events is statistically significant but not spectacular ". This is the reality of the data. The coveted 20% reduction for most cardio trials wasn't met. The article really points out the uphill road Esperion has in convincing cardiologist to prescribe. It was a good effort that fell short. Still admirably that a study was able to enroll close to 14,000 patients through a pandemic but very unfortunate that data wasn't robust.
Click to expand...


Grasping at straws buddy! First off what is Evaluate.com and who is Madeline Armstrong? Oh just looked her up.. she’s a FREAKING JOURNALIST!!! This is Laughable!!

Try researching for some Cardiologists
 






The ones I've talked to at the conference said basically the same thing. It is what it is. Get it through your head! It wasn't that great. Yes statistically significant but docs are looking for 20% reduction plus. 13% is okay just not great. Managed care will be the breaker and overcoming doctors impression of BA over the last 3 years. Having a rep cover huge geography especially with this being a relaunch will be important. This can't be done with the current group. Doctors are very skeptical of the selling skills of my fellow group of Esperion all-stars.
 






Dr Alexander and Dr O'Donahue think differently my friend. This wasn't a total win. LDL was still on average was 100. Also concern on incidence of gout. This was an average result study with not a great deal of ammunition to convince doctors to prescribe in the statin intolerant patient.
 
























anonymous said:
Dr Alexander and Dr O'Donahue think differently my friend. This wasn't a total win. LDL was still on average was 100. Also concern on incidence of gout. This was an average result study with not a great deal of ammunition to convince doctors to prescribe in the statin intolerant patient.
Click to expand...

What is the Number Needed to Treat to prevent 1 event ?
Oh, I am asking a Clinical question.
 


















Horseshit! BA has failed again. Stock now $4.48. A complete slaughter since last Saturday. If BA was a sick horse you would put it down. This madness has gone on long enough. This Board of Directors should be cleaning out their desks today and escorted by armed guards out of the building. Not one valid reason why BA can make it in such a crowded selling space. This has been one of the worst weeks for Esperion. Amazing the BOD haven't put up the white flag.
 






anonymous said:
Best time to buy dimwit! BA will be in all guidelines and this is just a matter of time. Also BA + EZ Nexlizet will be used post statins first before pcsk9’s.


HAVE NO FEAR !!!
Click to expand...
Yes, this is clearly a once in a lifetime opportunity when you look at how the market is shaping up and the clinical data that is now clearly in focus. You can see where there is a big leg up in our future long. Does it take you can’t help but think about where were likely to be in a year. The SVB failure is a wrinkle but this will be overcome.
 






Oh , here we go again with the one leg up guy. Who for the record couldn't pick a winner in a one horse race. Esperion is dead in the water. This couldn't of gone any worse.
 






Top Bottom
Back
Quote